Golimumab

From Infogalactic: the planetary knowledge core
Jump to: navigation, search
Golimumab
Monoclonal antibody
Type Whole antibody
Source Human
Target TNFα
Clinical data
Trade names Simponi
AHFS/Drugs.com monograph
MedlinePlus a610010
Licence data EMA:Link, US FDA:link
Legal status
Routes of
administration		 Subcutaneous injection
Identifiers
CAS Number 476181-74-5 N
ATC code L04AB06 (WHO)
UNII 91X1KLU43E YesY
KEGG D04358 YesY
ChEMBL CHEMBL1201833 N
Chemical data
Formula C6530H10068N1752O2026S44
Molecular mass 147 kDa
 NYesY (what is this?)  (verify)

Golimumab (CNTO 148)[1] is a human monoclonal antibody which is used as an immunosuppressive drug and marketed under the brand name Simponi. Golimumab targets tumor necrosis factor alpha (TNF-alpha), a pro-inflammatory molecule[2] and hence is a TNF inhibitor.

Golimumab was developed by Centocor and is approved in Canada[3] and the United States[4] as a once monthly subcutaneous treatment for adults with moderately to severely active rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.[5] Golimumab has been approved in 2013 for use in adults with moderately to severely active ulcerative colitis.

In the same year, Johnson & Johnson, the parent company of Centocor, also received an approval from European Medicines Agency (EMEA) for the use of golimumab as a treatment for rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis.[6] Golimumab is marketed by Merck & Co, Inc. in Europe, pending final arbitration between J&J and Merck.[7][8][9]

Clinical trials

Rheumatoid arthritis

Large, double-blind randomized controlled trials in patients with rheumatoid arthritis have shown that golimumab in combination with methotrexate was more effective than methotrexate alone.[10]

References

  1. ↑ Lua error in package.lua at line 80: module 'strict' not found.
  2. ↑ Statement On A Nonproprietary Name Adopted By The USAN Council – Golimumab, American Medical Association.
  3. ↑ Lua error in package.lua at line 80: module 'strict' not found. Apr 2009
  4. ↑ FDA Approves Simponi
  5. ↑ Lua error in package.lua at line 80: module 'strict' not found.
  6. ↑ Johnson & Johnson Reports 2008 First-Quarter Results
  7. ↑ FDA approves Johnson & Johnson rheumatoid arthritis drug golimumab
  8. ↑ [1] Merck sees fast ruling in J&J Remicade arbitration
  9. ↑ Lua error in package.lua at line 80: module 'strict' not found.
  10. ↑ Oldfield V, Plosker GL.[2].Biodrugs 2009;23(2):125-135. doi:10.2165/00063030-200923020-00005.
Retrieved from "https://infogalactic.com/w/index.php?title=Golimumab&oldid=4903131"